Quantifying patient preferences for symptomatic breast clinic referral: a decision analysis study by Quinlan, Aisling et al.
1Quinlan A, et al. BMJ Open 2018;8:e017286. doi:10.1136/bmjopen-2017-017286
Open Access 
Quantifying patient preferences for 
symptomatic breast clinic referral: a 
decision analysis study
Aisling Quinlan,1 Kirsty K O'Brien,1 Rose Galvin,1,2 Colin Hardy,1 Ronan McDonnell,1 
Doireann Joyce,3 Ronald D McDowell,1 Emma Aherne,1 Claire Keogh,1,4 
Katriona O'Sullivan,1 Tom Fahey1
To cite: Quinlan A, O'Brien KK, 
Galvin R, et al.  Quantifying 
patient preferences for 
symptomatic breast 
clinic referral: a decision 
analysis study. BMJ Open 
2018;8:e017286. doi:10.1136/
bmjopen-2017-017286
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2017- 
017286).
Received 19 April 2017
Revised 2 February 2018
Accepted 11 April 2018
1HRB Centre for Primary Care 
Research, Department of 
General Practice, Royal College 
of Surgeons in Ireland, Dublin, 
Ireland
2Department of Clinical 
Therapies, University of 
Limerick, Limerick, Ireland
3Department of Surgery, 
National University of Ireland 
Galway, Galway, Ireland
4School of Computer Science 
and Statistics, Trinity College 
Dublin, Dublin, Ireland
Correspondence to
Professor Tom Fahey;  
 tomfahey@ rcsi. ie
Research
AbstrACt
Objectives Decision analysis study that incorporates 
patient preferences and probability estimates to 
investigate the impact of women’s preferences for referral 
or an alternative strategy of watchful waiting if faced with 
symptoms that could be due to breast cancer.
setting Community-based study.
Participants Asymptomatic women aged 30–60 years.
Interventions Participants were presented with 11 health 
scenarios that represent the possible consequences 
of symptomatic breast problems. Participants were 
asked the risk of death that they were willing to take in 
order to avoid the health scenario using the standard 
gamble utility method. This process was repeated for 
all 11 health scenarios. Formal decision analysis for the 
preferred individual decision was then estimated for each 
participant.
Primary outcome measure The preferred diagnostic 
strategy was either watchful waiting or referral to a breast 
clinic. Sensitivity analysis was used to examine how each 
varied according to changes in the probabilities of the 
health scenarios.
results A total of 35 participants completed the 
interviews, with a median age 41 years (IQR 35–47 years). 
The majority of the study sample was employed (n=32, 
91.4%), with a third-level (university) education (n=32, 
91.4%) and with knowledge of someone with breast 
cancer (n=30, 85.7%). When individual preferences were 
accounted for, 25 (71.4%) patients preferred watchful 
waiting to referral for triple assessment as their preferred 
initial diagnostic strategy. Sensitivity analysis shows that 
referral for triple assessment becomes the dominant 
strategy at the upper probability estimate (18%) of breast 
cancer in the community.
Conclusions Watchful waiting is an acceptable strategy 
for most women who present to their general practitioner 
(GP) with breast symptoms. These findings suggest that 
current referral guidelines should take more explicit 
account of women’s preferences in relation to their GPs 
initial management strategy.
IntrOduCtIOn  
Between 2009 and 2011, it was reported that 
31% of cancers in Irish women were due to 
breast cancer, making it the most prevalent 
cancer in Irish women.1 In response, the 
National Cancer Control Programme clinical 
guidelines were introduced to streamline the 
referral process to symptomatic breast units. 
At present, general practitioners (GPs) act 
as gatekeepers for referral of women with 
breast symptoms. Referral to symptomatic 
breast clinics results in triple assessment: 
a three-step process comprising clinical, 
radiological and histological examination 
after fine-needle aspiration.2 Over the past 
10 years, the number of women referred to 
symptomatic breast clinics in Ireland has 
significantly increased, despite the fact that 
there has been no rise in breast cancer inci-
dence.2 In 2006, there were 23 575 new refer-
rals with 2137 breast cancer cases diagnosed; 
in 2009, there were 32 249 referrals and 1879 
breast cancer cases diagnosed; and in 2010, 
37 631 new referrals with 2012 new breast 
cancer cases diagnosed.3 4 Consequently, the 
malignant:benign ratio has altered from 1:10 
in 2006, to 1:16 in 2009, to 1:18 in 2010.4 The 
rise in these referrals for triple assessment 
strengths and limitations of this study
 ► Strength of this study is that it accounts for wom-
en’s preferences in relation to a watchful waiting or 
immediate referral strategy when faced with symp-
toms that could be due to breast cancer.
 ► Weakness is that the  preferences were elicited in 
asymptomatic women. Women with symptoms may 
express different preferences.
 ► The impact of eliciting preferences should be done 
in the context of a randomised trial of a decision aid 
that uses decision analysis as a form of shared de-
cision-making for women with symptoms that could 
be due to breast cancer.
 ► Taking account of women’s preferences might mean 
that significantly fewer women would be referred 
to symptomatic breast clinics with a consequent 
saving in investigations and costs, and reducing the 
burden of ‘medicalisation’ in women with benign 
breast disease.
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without an increase in breast cancer diagnosis means that 
more women are being exposed to invasive diagnostic 
investigations.
Clinical prediction rules (CPRs) are clinical tools 
that quantify the independent impact of factors from a 
patient’s history, physical examination and diagnostic 
tests, and stratify patients according to the probability 
of having a target disorder.5 Recently, CPRs have been 
derived and validated to calculate a patient’s risk of breast 
cancer,6 7 and have been proposed as methods to discrim-
inate between patients at high risk of breast cancer from 
low-risk patients. Such an approach may serve to decrease 
the number of unnecessary referrals to symptomatic 
breast clinics in women with a low probability of breast 
cancer. Patients who are considered low risk could, as an 
alternative, undergo a watchful-waiting strategy (up to 
6–8 weeks) with their GP. However, it is unclear from the 
current literature if patients who are considered low risk 
would find this acceptable.
Decision analysis is a technique to aid decision-making 
when uncertainty exists over the balance between bene-
fits and risks of treatment.8 Decision trees have been used 
to assess how patient’s preferences impact on diagnosis 
and treatment for conditions such as ovarian cancer9 
and atrial fibrillation.10 To date, little is known about 
how women who have symptomatic breast problems feel 
about the options of immediate referral or watching 
waiting in terms of referral to a symptomatic breast clinic. 
The aim of this study is to assess the impact of patient 
preferences for immediate referral to a specialist breast 
clinic or watchful waiting in primary care. We developed 
a decision tree and elicited patient’s preferences for these 
alternative diagnostic strategies by combining individual 
preferences with probability estimates of breast cancer 
using decision analysis.
MethOdOlOgy
study design
This study used decision analysis in the form of utility 
assessment and folding back a decision tree. The Strength-
ening the Reporting of Observational Studies in Epide-
miology standardised reporting guidelines were followed 
to ensure the standardised conduct and reporting of the 
research.
developing the decision tree and health scenarios
Literature searches were conducted in medical data-
bases such as PubMed, the Cochrane library and Web of 
Science to assist with the development of the decision 
tree and health scenarios. A specialist registrar with clin-
ical experience in a symptomatic breast clinic was also 
consulted during this development phase. Following 
these consultations, the decision tree was constructed 
to portray the temporal course of the two diagnostic 
options (figure 1). The decision tree had 1 decision node 
with 2 diagnostic branches (a choice between watchful 
waiting and immediate referral), 9 probability or chance 
nodes, and 11 health outcome nodes. In accordance 
with the literature, the tree was designed such that only 
two branches emanated from each chance node.11 The 
number of outcome nodes differed between the two 
Figure 1 Decision tree for health states in the treatment of breast cancer with utility values (median (IQR)) for each state. GP, 
general practitioner.
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branches of the tree in order to accommodate the addi-
tional step (an observation period before breast cancer 
assessment among patients who return to their GP) in 
the watchful waiting branch of the tree. It is not always 
possible or appropriate for each branch of a decision tree 
to have the same number of outcome nodes as this will be 
dependent on the nature and temporal order of events 
in that branch.12 The decision tree is ‘balanced’ as each 
branch has advantages and disadvantages, and hence it 
is not possible to readily identify a treatment path that is 
ideal in all respects.11
A total of 11 health scenarios were constructed; one for 
each outcome node. For this study, the standard gamble 
(SG) method of utility assessment was used.13 14 Briefly, 
participants were presented with a description of each 
health state, and its physical consequences and emotional 
consequences, and were given the opportunity to remain in 
the health state or to gamble it for perfect health, but with 
the risk of death if they took the gamble. Participants were 
presented with differing probabilities showing how the 
chance of perfect health and death varied with each other 
for each health state (the ‘ping-pong method’). The utility 
value was one minus the risk of death they were willing to 
take in order to avoid the health state described. The 11 
health states were presented in a random order. Details of 
the health states and the SG scenarios seen by the partici-
pants are provided in the online supplementary material.
Probability estimates for each chance node were 
obtained from the medical literature.6 7 15–27 Where 
possible, relevant probability estimates for each chance 
node were combined using random effects meta-anal-
ysis (table 1). The same probabilities were used for each 
participant. It was not possible to estimate from the litera-
ture the probability of a diagnosis of breast cancer among 
patients who returned to their doctor following a period 
of watchful waiting. Clinical experience suggested this 
would be several percentage points higher in absolute 
terms than the probability of a diagnosis of breast cancer 
following referral and triple assessment (RTA), and an 
estimate of 10% was used.
Table 1 Probability estimates used in the breast cancer decision tree analysis
Treatment path Outcome
Estimated probability 
(95% CI) References
Referral and triple assessment 
(RTA)
Breast cancer diagnosed subsequent 
to RTA.
0.06 (0.05 to 0.08) 6 7 22 23
Stage 1 breast cancer among patients 
diagnosed with breast cancer following 
RTA.
0.34 (0.26 to 0.42) 15–21
Stage 2 breast cancer among patients 
diagnosed with breast cancer following 
RTA.
0.46 (0.39 to 0.52) 15–21
Stage 3 breast cancer among patients 
diagnosed with breast cancer following 
RTA.
0.15 (0.13 to 0.17) 15–21
Stage 4 breast cancer among patients 
diagnosed with breast cancer following 
RTA.
0.05 (0.04 to 0.06) 15–21
Watchful waiting (WW) Symptoms do not resolve/worsen and 
patient returns to general practitioner 
(GP) following a period of WW.
0.34 (0.28 to 0.41) 24
Breast cancer diagnosed among 
patients who returned to GP following 
WW.
0.10 (0.05 to 0.18) Clinical estimate
Stage 1 breast cancer among patients 
diagnosed with breast cancer following 
WW.
0.27 (0.20 to 0.33) 25–27
Stage 2 breast cancer among patients 
diagnosed with breast cancer following 
WW.
0.42 (0.36 to 0.47) 25–27
Stage 3 breast cancer among patients 
diagnosed with breast cancer following 
WW.
0.20 (0.16 to 0.22) 25–27
Stage 4 breast cancer among patients 
diagnosed with breast cancer following 
WW.
0.11 (0.09 to 0.13) 25–27
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Participants and setting
Interviews were conducted over a 6-month period in 
Dublin from October 2014 to April 2015. Asymptomatic 
women aged 30–60 years were invited to participate in 
the study. Participants were recruited using university 
staff notice boards, social media and snowball sampling. 
The majority of interviews were carried out in a meeting 
room in the research building. Some interviews were 
conducted in peoples’ place of work as this was more 
convenient for them. Written informed consent was 
obtained from all participants prior to participation. The 
interviews were conducted with a researcher present who 
was available to answer any questions and to obtain feed-
back about the interview. Prior to the interview, partici-
pants were given a baseline demographics questionnaire 
and a multiple-choice questionnaire to assess their knowl-
edge of breast cancer. As this is a feasibility study for a 
proposed randomised controlled trial, no formal sample 
size was calculated. We excluded women with a current or 
previous history of breast cancer.
utility assessment
A computer-based assessment programme which 
presented and recorded participant responses was 
designed. This programme incorporated an intro-
duction, an explanation of the interview process and 
presentation of each clinical scenario in random order 
using the SG method of utility assessment. An example 
of the SG was included for orientation, and definitions 
were provided for any medical terminology used. The 
purpose of using a computer programme was to allow 
the interviewer to limit his/her interaction with each 
participant, standardise utility assessment and minimise 
interviewer bias. A pilot study was carried out and modi-
fications made to the computer programme and utility 
assessment process. See online supplementary table of 
health scenarios.
ethical approval and data protection
The data from the computer programme was stored 
with a participant ID only and saved to an encrypted 
password-protected desktop computer. To protect 
patient identity, a Microsoft Excel spreadsheet was 
created; containing just patient names and identification 
numbers, and this was stored in a secured, password-pro-
tected folder on the server and kept separate to the data 
from the interview.
decision analysis
The utility for each outcome, ‘a number assigned to 
the quality of life a patient would attach to a particular 
outcome on a defined scale’,12 was calculated as 1-risk of 
death (expressed as a fraction) a participant was willing to 
take in order to avoid the health scenario as described. For 
each participant, an expected utility score for each diag-
nostic option was obtained by multiplying and summing 
the relevant probabilities and utilities. The branch which 
had the highest expected utility score was determined to 
be the preferred diagnostic strategy—watchful waiting or 
referral for triple assessment.
Sensitivity analysis was used to determine the robust-
ness of the conclusion drawn from the decision tree.28 
For our study, each of the probability estimates derived 
from the literature was allowed to vary between the lower 
and upper limits of the 95% CI for that estimate, in order 
to assess the extent to which the preferred diagnostic 
strategy changed. The difference between the number 
of patients preferring watchful waiting using the upper 
limit of the 95% CI and the number of patients prefer-
ring watchful waiting using the lower limit of the 95% CI 
for each probability estimate (the swing) was squared and 
totalled; the impact of varying each of the probability esti-
mates was measured as a percentage of the total squared-
swing. The sensitivity analyses accounted for the fact that 
some probability estimates were used more than once 
by incorporating the conditioning event into the defi-
nition of the variables under consideration.29 An addi-
tional two-way sensitivity analysis explored how women’s 
preferred diagnostic option changed as the probability of 
diagnosis following watchful waiting varied relative to the 
probability of diagnosis following RTA.
Standard descriptive statistics were used to summarise 
the sample. Results were held to be significant if they 
referred to statistical significance on a two-sided test eval-
uated at the 5% level. All analyses were performed using 
STATA V.13 (StataCorp, 2013).
results
A total of 36 women participated, with 35 interviews 
completed in full. The median age of participants was 
41 years (IQR 35–47 years). The demographic details 
of participants are described in table 2. The majority of 
participants were employed (32, 91.4%), had a third-level 
(university) education (32, 91.4%) and knew someone 
with breast cancer (30, 85.7%). Less than half the study 
sample (15, 42.9%) reported having a prior mammog-
raphy. There was borderline evidence of a negative 
correlation between participants’ self-reported knowl-
edge of breast cancer and their actual knowledge based 
on responses to a multiple-choice questionnaire (p=0.06).
When patient preferences were taken into account, 25 
patients (71.4%, 95% CI 19% to 30%) preferred watchful 
waiting to referral as the initial diagnostic strategy. Sensi-
tivity analysis showed that the overall preferred diagnostic 
strategy changed to referral when the probability of breast 
cancer following a period of watchful waiting increased; 
only 10 women favoured watchful waiting when the prob-
ability of breast cancer following a period of watchful 
waiting had increased to 18% (table 3). Swings in the 
group preference according to changes in the probabili-
ties associated with each of the stage of breast cancer were 
small in comparison (table 3).
In terms of two-way sensitivity analysis, more than half 
the participating women still preferred watchful waiting 
when the probability of a diagnosis of breast cancer 
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following a period of watchful waiting was 2.25 times 
as high as the probability of diagnosis following RTA 
(figure 2). This pattern remained consistent irrespective 
of the probability of breast cancer following RTA, esti-
mated at levels of 4%, 6%, 8% and 10%.
dIsCussIOn
summary of main findings
This study shows that a strategy of watchful waiting in 
women with breast symptoms in primary care could be 
considered as an acceptable alternative to immediate 
referral to a symptomatic breast clinic, but this strategy of 
shared decision-making using decision analysis should be 
tested in a randomised controlled trial. Our observational 
findings suggest that women’s own preferences should 
form an important element of the decision to refer to 
a symptomatic breast clinic and that these preferences 
should be accounted as part of a shared decision-making 
process. Sensitivity analysis shows that as the probability of 
breast cancer increases, the diagnostic strategy of referral 
for triple assessment dominates. Two-way sensitivity anal-
ysis shows that, across the likely probability range of 
breast cancer under a watchful-waiting strategy, referral 
for triple assessment becomes the dominant strategy once 
the probability of breast cancer is two and a half times 
more likely than under a watchful-waiting strategy.
results in the context of the current literature
Although utility assessment has been used to evaluate the 
acceptability of various clinical states and treatment regi-
mens in the breast cancer literature,30–32 it has not been 
used to examine the acceptability of watchful waiting in 
low-risk patients presenting with signs and symptoms of 
possible breast cancer. A previous study that assessed the 
effects of alternative terms for ductal carcinoma in situ 
found that watchful waiting is acceptable to patients 
provided that research shows that watchful waiting is a 
safe and effective option.33 The preliminary findings from 
our study suggest that women may be prepared to accept 
a conservative, non-invasive strategy of watchful waiting 
when the probability of breast cancer is low.
Watchful waiting has also been described as a key tech-
nique for more effective management of other cancers 
such as prostate cancer.34 In prostate cancer, the use 
of prostate-specific antigen (PSA) testing has led to an 
increase in the incidence of prostate cancer but not a 
decrease in the mortality rate, suggesting that PSA testing 
often identifies low-risk cancers.35 Given the serious and 
common side effects associated with treatment in pros-
tate cancer, some studies have shown that some men 
prefer watchful waiting to treatment options.36 In our 
study, the side effects of further diagnostic testing (triple 
assessment) are less onerous than treatment of localised 
prostate cancer, but many women would experience high 
levels of anxiety and stress on referral to a symptomatic 
breast clinic. This study suggests that many women would 
find it more acceptable to undergo watchful waiting for a 
period rather than participate in diagnostic testing when 
their risk of breast cancer is low.
A qualitative study examining women’s views on overdi-
agnosis in breast cancer screening showed that 50% of 
the study population felt that they needed to make more 
careful personal decisions about screening and would 
consider watchful waiting as an alternative route if they 
were found to have a low-risk cancer.37 Like our study, 
watchful waiting was found to be an acceptable strategy 
when the risk involved is low, and the health outcomes 
are positive.
strengths and limitations
This study has several strengths. We used an evidence-
based approach, quantifying probabilities from the liter-
ature and developing health states that incorporate the 
common features of breast cancer. We tested and modi-
fied the wording of the health states and the computer 
programme in a pilot group of participants and refined 
our protocol based on feedback from these participants. 
We tried to limit any bias caused by the interviewer by 
Table 2 Descriptive statistics for the study sample (n=35 
participants)
Variable Median (IQR)
Age (years) 41 (35–47)
Self-rated knowledge of 
breast cancer (maximum 
score 10) 
5 (4–7)
Actual knowledge of breast 
cancer (maximum score 7) 
3 (2–4)
Number of participants (%)
Location 
  Dublin and surrounds 23 (65.7)
  West of Ireland 10 (28.6)
  Overseas 2 (5.7)
Education 
  Secondary school 3 (8.6)
  Third level (university) 32 (91.4)
Employed 
  Yes 32 (91.4)
  No 3 (8.6)
Family carer 
  Yes 18 (51.4)
  No 17 (49.6)
Know someone with breast 
cancer 
  Yes 30 (85.7)
  No 5 (14.3)
Have had a mammography 
  Yes 15 (42.9)
  No 20 (57.1)
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using a computer programme and providing the partici-
pant with written definitions and information. Examples 
of the SG were given to the participants prior to the inter-
view, so participants had the opportunity to familiarise 
themselves with the method. Although the sample was 
relatively small, it included participants with a range of 
ages and knowledge of breast cancer. We acknowledge 
that the sample of participants is not representative of the 
population at large, that women were asymptomatic and 
that preferences may change or be different when faced 
Table 3 Sensitivity analysis for breast cancer patient treatment preference study
Health scenario
Values for sensitivity analysis
Number of patients preferring WW 
to RTA
Swing Swing2 %Swing2
Lower 
limit for 
probability
Reference 
probability
Upper 
limit for 
probability
Lower 
limit for 
probability
Reference 
probability
Upper 
limit for 
probability
Diagnosis of breast 
cancer following RTA
0.05 0.06 0.08 23 25 27 4 16 3.21
Stage 1 breast 
cancer among 
patients diagnosed 
following RTA
0.26 0.34 0.42 26 25 21 −5 25 5.02
Stage 2 breast 
cancer among 
patients diagnosed 
following RTA
0.39 0.46 0.52 26 25 24 −2 4 0.80
Stage 3 breast 
cancer among 
patients diagnosed 
following RTA
0.13 0.15 0.17 25 25 25 0 0 0.00
Stage 4 breast 
cancer among 
patients diagnosed 
following RTA
0.04 0.05 0.06 25 25 25 0 0 0.00
Symptoms do not 
resolve/worsen and 
patient returns to 
GP following period 
of WW
0.28 0.34 0.41 27 25 24 −3 9 1.81
Diagnosis of breast 
cancer among 
patients returning 
to GP after period 
of WW
0.05 0.10 0.18 31 25 10 −21 441 88.55
Stage 1 breast 
cancer among 
patients diagnosed 
following WW
0.20 0.26 0.33 25 25 26 1 1 0.20
Stage 2 breast 
cancer among 
patients diagnosed 
following WW
0.36 0.41 0.47 25 25 26 1 1 0.20
Stage 3 breast 
cancer among 
patients diagnosed 
following WW
0.16 0.19 0.22 25 25 25 0 0 0
Stage 4 breast 
cancer among 
patients diagnosed 
following WW
0.09 0.11 0.13 26 25 25 1 −1 0.20
Swing=number of patients preferring WW to RTA (upper limit for probability)−number of patients preferring WW to RTA (lower limit for 
probability).
Swing2=swing×swing.
%Swing=swing2x100/(total swing2 (=498)).
GP, general practitioner; RTA, referral and triple assessment; WW, watchful waiting.
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with possible symptoms of breast cancer—a breast lump 
or nipple change. However, our results suggest that when 
preferences about a watchful-waiting strategy is elicited, 
many women are happy to adopt this approach. Based on 
these provisional results, we hope to develop a decision 
aid for women with symptomatic breast problems and test 
its value in a randomised controlled trial.
Clinical and policy implications
The current referral process leads to many patients 
who are at low risk of breast cancer being referred to 
busy symptomatic breast clinics, with a risk of iatrogenic 
harm, increased patient anxiety and overmedicalising 
of a self-limiting condition. With more emphasis on the 
development of CPRs, it will be possible to identify and 
quantify each individual woman’s risk of breast cancer. 
A recent study derived a CPR for predicting the risk of 
breast cancer for women presenting to their GP with 
breast symptoms.7 A total of 6590 patients were included 
in the derivation study, and 4.9% were diagnosed with 
breast cancer. Independent clinical predictors for breast 
cancer were: increasing age by year (adjusted OR 1.08, 
95% CI 1.07 to 1.09), presence of a lump (5.63, 95% CI 
4.2 to 7.56), nipple change (2.77, 95% CI 1.68 to 4.58) 
and nipple discharge (2.09, 95% CI 1.1 to 3.97). Valida-
tion of the rule (n=911) also shows that the probability 
of breast cancer is higher with an increasing number of 
these independent clinical variables. By incorporating 
patient preferences with an individual’s probability of 
breast cancer from a CPR, a strategy of watchful waiting is 
acceptable, cost-effective and likely to avoid considerable 
iatrogenic harm. Clinical practice guidelines should 
incorporate probability estimates of breast cancer based 
on CPRs and urge elicitation of patient preference for 
alternative diagnostic options—watchful waiting or 
referral; more formally, decision aids that could be devel-
oped in conjunction with the symptomatic breast CPRs 
to enable the alternative options of watchful waiting or 
referral based on individual preferences.
COnClusIOn
This study suggests that watchful waiting may be an 
acceptable diagnostic strategy for women who present to 
their GP with breast symptoms. These findings should be 
validated in a larger and more comprehensive study of 
patient preferences in women with breast symptoms in a 
randomised controlled trial. Clinical practice guidelines 
should reflect the importance of eliciting women’s pref-
erences for watchful waiting as an alternative to referral 
to a symptomatic breast clinic, particularly in women with 
low-risk clinical features.
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